RT Journal Article
T1 Combating virulence of Gram-negative bacilli by OmpA inhibition.
A1 Vila-Farres, Xavier
A1 Parra-Millan, Raquel
A1 Sanchez-Encinales, Viviana
A1 Varese, Monica
A1 Ayerbe-Algaba, Rafael
A1 Bayo, Nuria
A1 Guardiola, Salvador
A1 Pachon-Ibañez, María Eugenia
A1 Kotev, Martin
A1 Garcia, Jesus
A1 Teixido, Meritxell
A1 Vila, Jordi
A1 Pachon, Jeronimo
A1 Giralt, Ernest
A1 Smani, Younes
K1 Drug discovery and development
K1 Pathogens
AB Preventing the adhesion of pathogens to host cells provides an innovative approach to tackling multidrug-resistant bacteria. In this regard, the identification of outer membrane protein A (OmpA) as a key bacterial virulence factor has been a major breakthrough. The use of virtual screening helped us to identify a cyclic hexapeptide AOA-2 that inhibits the adhesion of Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli to host cells and the formation of biofilm, thereby preventing the development of infection in vitro and in a murine sepsis peritoneal model. Inhibition of OmpA offers a strategy as monotherapy to address the urgent need for treatments for infections caused by Gram-negative bacilli.
PB Nature Publishing Group
YR 2017
FD 2017-10-31
LK http://hdl.handle.net/10668/11756
UL http://hdl.handle.net/10668/11756
LA en
NO Vila-Farrés X, Parra-Millán R, Sánchez-Encinales V, Varese M, Ayerbe-Algaba R, Bayó N, et al. Combating virulence of Gram-negative bacilli by OmpA inhibition. Sci Rep. 2017 Oct 31;7(1):1-11.
NO We thank V. López Casado, A. Gardel, C. Tomi, and C. Garcia for technical help, and J. Sánchez Céspedes for critical review of this manuscript. We also acknowledge the NMR facility of the University of Barcelona (CCiT UB). This study was supported by the Consejería de Salud y Bienestar (grant PI12–0069), the Consejería de Economia, Innovación, Ciencia y Empleo (grants CTS-6173/12, and 2014LLAV-00064) of Andalusia, Spain, and by Plan Nacional de I + D + i 2008–2011 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0001) co-financed by European Development Regional Fund “A way to achieve Europe”. This work led to the provisional patent application ES P201431400. Y. Smani is supported by the Subprograma Miguel Servet Tipo I from the Ministerio de Economía y Competitividad of Spain [CP15/01358]. IRB Barcelona is the recipient of a Severo Ochoa Award of Excellence from MINECO (Government of Spain).
DS RISalud
RD Apr 12, 2025